DE69941707D1 - Methode zur verminderung der immunerkennung - Google Patents

Methode zur verminderung der immunerkennung

Info

Publication number
DE69941707D1
DE69941707D1 DE69941707T DE69941707T DE69941707D1 DE 69941707 D1 DE69941707 D1 DE 69941707D1 DE 69941707 T DE69941707 T DE 69941707T DE 69941707 T DE69941707 T DE 69941707T DE 69941707 D1 DE69941707 D1 DE 69941707D1
Authority
DE
Germany
Prior art keywords
arginine
nitric oxide
inhibitor
immune detection
gelatin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69941707T
Other languages
English (en)
Inventor
Anton-Lewis Usala
Richard Chris Klann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Encelle Inc
Original Assignee
Encelle Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/346,212 external-priority patent/US6352707B1/en
Application filed by Encelle Inc filed Critical Encelle Inc
Application granted granted Critical
Publication of DE69941707D1 publication Critical patent/DE69941707D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/022—Artificial gland structures using bioreactors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/222—Gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/26—Mixtures of macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/52—Hydrogels or hydrocolloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/126—Immunoprotecting barriers, e.g. jackets, diffusion chambers
    • A61K2035/128—Immunoprotecting barriers, e.g. jackets, diffusion chambers capsules, e.g. microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
    • A61L2300/114—Nitric oxide, i.e. NO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/204—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with nitrogen-containing functional groups, e.g. aminoxides, nitriles, guanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/21—Acids
    • A61L2300/214—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/23—Carbohydrates
    • A61L2300/236—Glycosaminoglycans, e.g. heparin, hyaluronic acid, chondroitin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/432—Inhibitors, antagonists
    • A61L2300/434—Inhibitors, antagonists of enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/40—Preparation and treatment of biological tissue for implantation, e.g. decellularisation, cross-linking
DE69941707T 1998-07-10 1999-07-09 Methode zur verminderung der immunerkennung Expired - Lifetime DE69941707D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/113,437 US6231881B1 (en) 1992-02-24 1998-07-10 Medium and matrix for long-term proliferation of cells
US09/346,212 US6352707B1 (en) 1992-02-24 1999-07-01 Transplant encapsulation in a hydrogel matrix to obscure immune recognition
PCT/US1999/015465 WO2000002600A1 (en) 1998-07-10 1999-07-09 Method of obscuring immune recognition

Publications (1)

Publication Number Publication Date
DE69941707D1 true DE69941707D1 (de) 2010-01-07

Family

ID=22349408

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69941707T Expired - Lifetime DE69941707D1 (de) 1998-07-10 1999-07-09 Methode zur verminderung der immunerkennung

Country Status (9)

Country Link
US (5) US6231881B1 (de)
EP (1) EP1098959A2 (de)
JP (1) JP2002520013A (de)
AT (2) ATE326243T1 (de)
AU (1) AU758833B2 (de)
CA (1) CA2332701C (de)
DE (1) DE69941707D1 (de)
ES (1) ES2337320T3 (de)
WO (1) WO2000002999A2 (de)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6703017B1 (en) 1994-04-28 2004-03-09 Ixion Biotechnology, Inc. Reversal of insulin-dependent diabetes by islet-producing stem cells, islet progenitor cells and islet-like structures
US7070607B2 (en) * 1998-01-27 2006-07-04 The Regents Of The University Of California Bioabsorbable polymeric implants and a method of using the same to create occlusions
US6905707B2 (en) * 1998-05-28 2005-06-14 Medical Research Institute Controlled release arginine alpha ketoglutarate
EP1025861A1 (de) * 1999-02-04 2000-08-09 Roche Diagnostics GmbH Pharmazeutische Zusammensetzung von hydrophob modifizierten Hedgehog-Proteinen und deren Verwendung
ATE468122T1 (de) * 1999-04-30 2010-06-15 Neurotrophincell Pty Ltd Xenotransplant für zns therapie
US20050265977A1 (en) * 1999-04-30 2005-12-01 Elliott Robert B Xenotransplant for CNS therapy
US20090047325A1 (en) * 1999-04-30 2009-02-19 Neurotrophincell Pty. Limited Xenotransplant for cns therapy
WO2001019962A2 (en) * 1999-09-15 2001-03-22 Encelle, Inc. Method of preserving tissue viability during mechanical separation process
DK1248640T3 (da) * 2000-01-20 2007-02-12 Diabcell Pty Ltd Xenotransplantation af svineöer og deres fremstilling
CA2410965C (en) * 2000-05-31 2010-09-14 Encelle, Inc. Method of stimulating hair growth
AU2002211122B2 (en) * 2000-10-17 2005-06-23 Diatranz Otsuka Limited Preparation and xenotransplantation or porcine islets
US20020188170A1 (en) * 2001-04-27 2002-12-12 Santamore William P. Prevention of myocardial infarction induced ventricular expansion and remodeling
WO2002092783A2 (en) * 2001-05-15 2002-11-21 Children's Medical Center Corporation Methods and apparatus for application of micro-mechanical forces to tissues
US20040097401A1 (en) * 2002-11-14 2004-05-20 Debatosh Datta Lysine in therapeutic angiogenesis, particularly in treating ischaemic conditions
US6702744B2 (en) 2001-06-20 2004-03-09 Advanced Cardiovascular Systems, Inc. Agents that stimulate therapeutic angiogenesis and techniques and devices that enable their delivery
US7156877B2 (en) 2001-06-29 2007-01-02 The Regents Of The University Of California Biodegradable/bioactive nucleus pulposus implant and method for treating degenerated intervertebral discs
US6790455B2 (en) * 2001-09-14 2004-09-14 The Research Foundation At State University Of New York Cell delivery system comprising a fibrous matrix and cells
US8608661B1 (en) 2001-11-30 2013-12-17 Advanced Cardiovascular Systems, Inc. Method for intravascular delivery of a treatment agent beyond a blood vessel wall
US7303814B2 (en) 2002-02-21 2007-12-04 Encelle, Inc. Immobilized bioactive hydrogel matrices as surface coatings
US20080086792A1 (en) 2006-10-13 2008-04-17 Thomas Charles Kuracina Method and apparatus for diverting sweat, liquid, moisture or the like from an eye
US20030228287A1 (en) * 2002-06-07 2003-12-11 Regents Of The University Of California Maintenance of islet cells
US7361368B2 (en) 2002-06-28 2008-04-22 Advanced Cardiovascular Systems, Inc. Device and method for combining a treatment agent and a gel
JP2005534303A (ja) * 2002-07-30 2005-11-17 マサチューセッツ・インスティテュート・オブ・テクノロジー 初代肝細胞の潅流法およびプレーティング法、ならびにこれに使用する培地
EP1391284A1 (de) * 2002-08-23 2004-02-25 Kasai Kogyo Co., Ltd. Schichtverbund und dessen Herstellungsverfahren
US8383158B2 (en) 2003-04-15 2013-02-26 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
US8038991B1 (en) 2003-04-15 2011-10-18 Abbott Cardiovascular Systems Inc. High-viscosity hyaluronic acid compositions to treat myocardial conditions
US8821473B2 (en) 2003-04-15 2014-09-02 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
AU2004285480B2 (en) * 2003-10-22 2010-12-16 Encelle, Inc. Bioactive hydrogel compositions for regenerating connective tissue
US20050245905A1 (en) * 2004-04-30 2005-11-03 Schmidt Steven P Local drug-delivery system
EP1773981A1 (de) * 2004-07-12 2007-04-18 Sorin Group Italia S.R.L. Vorrichtung und verfahren zur anzucht menschlicher zellen
US7784697B2 (en) 2004-12-23 2010-08-31 University Of Washington Methods of driving a scanning beam device to achieve high frame rates
US20060178696A1 (en) * 2005-02-04 2006-08-10 Porter Stephen C Macroporous materials for use in aneurysms
US9427496B2 (en) 2005-02-18 2016-08-30 Drexel University Method for creating an internal transport system within tissue scaffolds using computer-aided tissue engineering
US20080125745A1 (en) 2005-04-19 2008-05-29 Shubhayu Basu Methods and compositions for treating post-cardial infarction damage
US9539410B2 (en) 2005-04-19 2017-01-10 Abbott Cardiovascular Systems Inc. Methods and compositions for treating post-cardial infarction damage
US8187621B2 (en) 2005-04-19 2012-05-29 Advanced Cardiovascular Systems, Inc. Methods and compositions for treating post-myocardial infarction damage
US8303972B2 (en) 2005-04-19 2012-11-06 Advanced Cardiovascular Systems, Inc. Hydrogel bioscaffoldings and biomedical device coatings
US8828433B2 (en) 2005-04-19 2014-09-09 Advanced Cardiovascular Systems, Inc. Hydrogel bioscaffoldings and biomedical device coatings
US9942511B2 (en) 2005-10-31 2018-04-10 Invention Science Fund I, Llc Preservation/degradation of video/audio aspects of a data stream
NZ540597A (en) * 2005-06-08 2007-02-23 Neurotrophincell Pty Ltd A method for preventing the onset of type I diabetes comprising administering an implantable composition comprising living choroid plexus cells
US7947759B2 (en) * 2005-08-08 2011-05-24 Angstrom Medica Cement products and methods of making and using the same
DE102005054937A1 (de) * 2005-11-17 2007-05-24 Gelita Ag Angiogenese förderndes Substrat
CN101511169A (zh) 2005-11-30 2009-08-19 麻省理工学院 病原体检测细胞保存系统
US20070231901A1 (en) * 2005-12-02 2007-10-04 Shuichi Takayama Microfluidic cell culture media
EP1968628A2 (de) * 2005-12-28 2008-09-17 Essential Skincare, LLC Transferrin und transferrin-basierte zusammensetzungen zur diabetesbehandlung
US8999933B2 (en) * 2006-01-18 2015-04-07 Biolitec Pharma Marketing Ltd Photodynamic cosmetic procedure and healing method
WO2007087570A2 (en) * 2006-01-24 2007-08-02 Northfield Laboratories, Inc. Polymerized hemoglobin media and its use in isolation and transplantation of islet cells
US20090004159A1 (en) * 2006-01-24 2009-01-01 The Board Of Trustees Of The University Of Illinoi Polymerized Hemoglobin Media and Its Use in Isolation and Transplantation of Islet Cells
US7732190B2 (en) 2006-07-31 2010-06-08 Advanced Cardiovascular Systems, Inc. Modified two-component gelation systems, methods of use and methods of manufacture
US9242005B1 (en) 2006-08-21 2016-01-26 Abbott Cardiovascular Systems Inc. Pro-healing agent formulation compositions, methods and treatments
US20080069855A1 (en) * 2006-08-21 2008-03-20 Bonutti Peter M Method of inhibiting the formation of adhesions and scar tissue and reducing blood loss
CN101517067B (zh) * 2006-09-21 2014-08-06 特苏詹尼斯公司 细胞递送基质
US9005672B2 (en) 2006-11-17 2015-04-14 Abbott Cardiovascular Systems Inc. Methods of modifying myocardial infarction expansion
US8741326B2 (en) 2006-11-17 2014-06-03 Abbott Cardiovascular Systems Inc. Modified two-component gelation systems, methods of use and methods of manufacture
US8192760B2 (en) 2006-12-04 2012-06-05 Abbott Cardiovascular Systems Inc. Methods and compositions for treating tissue using silk proteins
EP2117470B1 (de) 2007-02-06 2013-03-06 Pioneer Surgical Technology, Inc. Bandscheibenimplantatvorrichtung
PL2155248T3 (pl) 2007-04-12 2015-12-31 Brigham & Womens Hospital Inc Celowanie w ABCB5 w terapii nowotworowej
AU2008248261A1 (en) 2007-05-01 2008-11-13 The Brigham And Women's Hospital, Inc. Wound healing device
DE102007024239A1 (de) * 2007-05-16 2008-11-20 Gelita Ag Angiogenese förderndes Substrat
US8815973B2 (en) * 2007-08-28 2014-08-26 Pioneer Surgical Technology, Inc. Cement products and methods of making and using the same
US20120301444A1 (en) * 2007-09-27 2012-11-29 Clarke Diana L Amnion-derived cell compositions, methods of making and uses thereof
US20090090214A1 (en) * 2007-10-04 2009-04-09 Chung Yuan Christian University Method for forming nano-scale metal particles
EP2222159B1 (de) * 2007-11-20 2018-02-21 Pioneer Surgical Orthobiologics, Inc. Kryokonservierung von zellen mittels vernetzten bioaktiven hydrogel matrixteilchen
EP2273952B1 (de) 2008-04-02 2018-02-21 Pioneer Surgical Technology, Inc. Bandscheibenimplantatvorrichtungen zur unterstützung der wirbel und vorrichtungen zu ihrer einführung
WO2009137074A1 (en) * 2008-05-06 2009-11-12 Indigene Pharmaceuticals, Inc. Compositions and methods for treating diabetic ulcers
SG178565A1 (en) 2009-08-28 2012-04-27 Sernova Corp Methods and devices for cellular transplantation
US9700650B2 (en) 2009-11-09 2017-07-11 Spotlight Technology Partners Llc Polysaccharide based hydrogels
US8795727B2 (en) 2009-11-09 2014-08-05 Spotlight Technology Partners Llc Fragmented hydrogels
US20110274666A1 (en) * 2010-05-07 2011-11-10 University Of North Carolina At Chapel Hill Method of engrafting cells from solid tissues
EP2625264B1 (de) 2010-10-08 2022-12-07 Terumo BCT, Inc. Verfahren und systeme für züchtung und ernte von zellen in einem hohlfaser-bioreaktorsystem mit steuerungsbedingungen
JP5808631B2 (ja) * 2011-09-29 2015-11-10 富士フイルム株式会社 血管新生用足場、及び再生医療用の血管の製造方法
US9132021B2 (en) 2011-10-07 2015-09-15 Pioneer Surgical Technology, Inc. Intervertebral implant
CA2854160A1 (en) 2011-11-02 2013-05-10 Halscion, Inc. Methods and compositions for wound treatment
CA2860227C (en) 2011-12-23 2020-03-24 Pioneer Surgical Technology Continuous matrix with osteoconductive particles dispersed therein, method of forming thereof, and method of regenerating bone therewith
EP2820428A1 (de) 2012-03-01 2015-01-07 3M Innovative Properties Company Verfahren zur förderung von wundheilung
US9101707B2 (en) 2012-04-27 2015-08-11 Gregory Zeltser Implantable bioartificial perfusion system
CA2886109A1 (en) * 2012-12-07 2014-06-12 Kansas State University Research Foundation Peptide-albumin hydrogel properties and its applications
EP2964238B1 (de) 2013-02-19 2021-01-13 Children's Medical Center Corporation Abcb5(+)-stammzellen zur behandlung von augenerkrankungen
WO2014182994A1 (en) 2013-05-10 2014-11-13 Children's Medical Center Corporation Wound healing and tissue engineering
WO2014208381A1 (ja) * 2013-06-28 2014-12-31 株式会社日本生物製剤 肝細胞増殖剤
WO2015073913A1 (en) 2013-11-16 2015-05-21 Terumo Bct, Inc. Expanding cells in a bioreactor
US11008547B2 (en) 2014-03-25 2021-05-18 Terumo Bct, Inc. Passive replacement of media
US20160090569A1 (en) 2014-09-26 2016-03-31 Terumo Bct, Inc. Scheduled Feed
AU2016209386A1 (en) 2015-01-20 2017-08-03 MiRagen Therapeutics, Inc. miR-92 inhibitors and uses thereof
EP3288556A4 (de) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Oral zerfallende zusammensetzungen
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
EP3464565A4 (de) 2016-05-25 2020-01-01 Terumo BCT, Inc. Zellexpansion
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US10815456B2 (en) 2016-10-04 2020-10-27 Transwell Biotech Co., Ltd. Composition, kit and method for cryopreserving cells
US11629332B2 (en) 2017-03-31 2023-04-18 Terumo Bct, Inc. Cell expansion
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
WO2019021143A1 (en) * 2017-07-22 2019-01-31 Rangasamy Naidu Educational Trust HYDROGEL BASED ON L-HISTIDINE MOLECULES
CA3074834A1 (en) 2017-09-08 2019-03-14 Pioneer Surgical Technology, Inc. Intervertebral implants, instruments, and methods
USD907771S1 (en) 2017-10-09 2021-01-12 Pioneer Surgical Technology, Inc. Intervertebral implant

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4477567A (en) 1977-12-01 1984-10-16 Connaught Laboratories Limited Continuous bovine beta cell line
US4198479A (en) 1979-03-30 1980-04-15 Merck & Co., Inc. Replacement of animal serum proteins by human albumin for growth and interferon production by Namalva cells
US4520821A (en) 1982-04-30 1985-06-04 The Regents Of The University Of California Growing of long-term biological tissue correction structures in vivo
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US5132223A (en) 1983-11-10 1992-07-21 Thomas Jefferson University Process and medium for cloning and long-term serial cultivation of adult human endothelial cells
US4868121A (en) 1985-02-07 1989-09-19 Mcdonnell Douglas Corporation Islet isolation process
US4978616A (en) 1985-02-28 1990-12-18 Verax Corporation Fluidized cell cultivation process
NO166836C (no) * 1985-03-14 1991-09-11 Univ California Fremgangsmaate for behandling av et organtransplantat.
US4997753A (en) 1985-04-04 1991-03-05 Verax Corporation Weighted collagen microsponge for immobilizing bioactive material
US4863856A (en) 1985-04-04 1989-09-05 Verax Corporation Weighted collagen microsponge for immobilizing bioactive materials
US5100783A (en) 1985-05-10 1992-03-31 Verax Corporation Weighted microsponge for immobilizing bioactive material
EP0213908A3 (de) 1985-08-26 1989-03-22 Hana Biologics, Inc. Transplantierbares Kunstgewebe und Verfahren
US4902295A (en) 1985-08-26 1990-02-20 Hana Biologics, Inc. Transplantable artificial tissue
GB8604497D0 (en) 1986-02-24 1986-04-03 Connaught Lab Separation of islets of langerhans
FR2600076A1 (fr) 1986-06-12 1987-12-18 Fond Ctre Nal Transfusion Milieu de culture comportant de l'albumine humaine, procede de preparation d'un produit injectable a partir de ce milieu, produit obtenu et son utilisation, composition obtenue
US5079160A (en) 1987-06-08 1992-01-07 Lacy Paul E Method to isolate clusters of cell subtypes from organs
US5457093A (en) * 1987-09-18 1995-10-10 Ethicon, Inc. Gel formulations containing growth factors
EP0403650B1 (de) * 1988-03-09 1994-05-25 Terumo Kabushiki Kaisha Für zellen eindringbares medizinisches material und kunsthaut
US4950483A (en) 1988-06-30 1990-08-21 Collagen Corporation Collagen wound healing matrices and process for their production
EP0363125A3 (de) 1988-10-03 1990-08-16 Hana Biologics Inc. Produkt, enthaltend vermehrungsfähige Bauchspeicheldrüsen-Endokrinezellen, und Verfahren
US4957902A (en) * 1988-12-20 1990-09-18 Board Of Regents, The University Of Texas System Peptide inhibitors of wound contraction
US5196185A (en) * 1989-09-11 1993-03-23 Micro-Collagen Pharmaceutics, Ltd. Collagen-based wound dressing and method for applying same
WO1991009119A1 (en) 1989-12-13 1991-06-27 Trancel Corporation Improved alginate microcapsules, methods of making and using same
US5645591A (en) 1990-05-29 1997-07-08 Stryker Corporation Synthetic bone matrix
US5336616A (en) 1990-09-12 1994-08-09 Lifecell Corporation Method for processing and preserving collagen-based tissues for transplantation
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
US5192312A (en) 1991-03-05 1993-03-09 Colorado State University Research Foundation Treated tissue for implantation and methods of treatment and use
EP0585368B1 (de) 1991-04-25 1997-08-06 Brown University Research Foundation Implantierbare, biokompatible immunisolator-trägersubstanz zum abgeben ausgesuchter, therapeutischer produkte
US5605938A (en) 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
ATE215605T1 (de) 1991-06-24 2002-04-15 Pacific Biomedical Res Inc In langzeitkultur gehaltene hormon-absondernde pankreatische zellen
CA2071137A1 (en) 1991-07-10 1993-01-11 Clarence C. Lee Composition and method for revitalizing scar tissue
US5116753A (en) 1991-07-30 1992-05-26 The Salk Institute For Biological Studies Maintenance of pancreatic islets
US5591709A (en) * 1991-08-30 1997-01-07 Life Medical Sciences, Inc. Compositions and methods for treating wounds
WO1994015589A1 (en) 1992-12-30 1994-07-21 Clover Consolidated, Limited Cytoprotective, biocompatible, retrievable macrocapsule containment systems for biologically active materials
US5824331A (en) 1992-02-24 1998-10-20 Encelle, Inc. Bioartificial devices and cellular matrices therefor
WO1993016685A1 (en) 1992-02-24 1993-09-02 Encelle, Inc. Bioartificial endocrine device
US5834005A (en) 1992-02-24 1998-11-10 Encelle, Inc. Bioartificial devices and cellular matrices therefor
US5830492A (en) 1992-02-24 1998-11-03 Encelle, Inc. Bioartificial devices and cellular matrices therefor
WO1993024112A1 (en) 1992-05-29 1993-12-09 Vivorx, Incorporated Microencapsulation of cells
CA2140905A1 (en) 1992-07-29 1994-01-30 Keith E. Dionne Use of pouch of implantation of living cells
US5262055A (en) 1992-10-19 1993-11-16 The University Of Utah Implantable and refillable biohybrid artificial pancreas
DE4431598C2 (de) 1993-03-03 1997-03-20 Michael Sittinger Verfahren zum Herstellen eines Implantates aus Zellkulturen
US5405772A (en) 1993-06-18 1995-04-11 Amgen Inc. Medium for long-term proliferation and development of cells
ATE317397T1 (de) 1993-11-17 2006-02-15 Athena Neurosciences Inc Transparente flüssigkeit zur verabreichung von verkapselten medikamenten
DK1418228T3 (da) 1994-01-13 2006-07-17 Rogosin Inst Makroindkapslede sekretoriske celler
US5512477A (en) 1994-04-21 1996-04-30 Genzyme Corporation Serum-free medium supplement
US5716404A (en) 1994-12-16 1998-02-10 Massachusetts Institute Of Technology Breast tissue engineering
US5840059A (en) 1995-06-07 1998-11-24 Cardiogenesis Corporation Therapeutic and diagnostic agent delivery
WO1997002569A1 (en) 1995-07-03 1997-01-23 Autronic Plastics, Inc. Package and storage unit for digital information storage media
US5681587A (en) 1995-10-06 1997-10-28 Desmos, Inc. Growth of adult pancreatic islet cells
US5672361A (en) 1996-03-29 1997-09-30 Desmos, Inc. Laminin 5 for growth of pancreatic islet cells
CA2179341A1 (en) 1996-04-12 1997-10-13 Gregory S. Korbutt Methods for isolating, enriching and increasing the maturation of cells
AU730749B2 (en) 1996-07-25 2001-03-15 Genzyme Corporation Chondrocyte media formulations and culture procedures
EP0939797B1 (de) 1996-10-11 2007-03-07 Invitrogen Corporation Definierte systeme zur kultivieurng epithelialer zellen und anwendung derselben

Also Published As

Publication number Publication date
CA2332701A1 (en) 2000-01-20
AU758833B2 (en) 2003-04-03
US20010019841A1 (en) 2001-09-06
US20010010826A1 (en) 2001-08-02
US6261587B1 (en) 2001-07-17
US20010007658A1 (en) 2001-07-12
US6713079B2 (en) 2004-03-30
ATE326243T1 (de) 2006-06-15
JP2002520013A (ja) 2002-07-09
AU4977299A (en) 2000-02-01
ES2337320T3 (es) 2010-04-22
ATE449619T1 (de) 2009-12-15
US6315994B2 (en) 2001-11-13
US6231881B1 (en) 2001-05-15
EP1098959A2 (de) 2001-05-16
CA2332701C (en) 2010-04-20
WO2000002999A3 (en) 2000-04-20
WO2000002999A2 (en) 2000-01-20
US6730315B2 (en) 2004-05-04

Similar Documents

Publication Publication Date Title
DE69941707D1 (de) Methode zur verminderung der immunerkennung
ATE321126T1 (de) Hydrogelmatrix für zellgewebelagerung
BR9913517A (pt) Composição, dispositivo, e, uso de uma composição
CA2410965A1 (en) Method of stimulating hair growth
NO954188D0 (no) Modifisert-protein- og -peptid - farmasöytika
BR0107703A (pt) Flavivìrus recombinantes e processos para uso dos mesmos
DE69834136D1 (de) Gefrierschutzprotein
EA200300377A1 (ru) Производные 2-амино-2-алкил-5-гептеновой и -гептиновой кислот, которые могут быть использованы в качестве ингибиторов синтетазы оксида азота
DE60122886D1 (de) Urea-injektor im gehaeuse eines abgas - turboladers
ATE409721T1 (de) Hydrophobin als beschichtungsmittel für expandierbare oder expandierte, thermoplastische polymerpartikel
DK1276763T3 (da) Anti-fryseproteiner, deres fremstilling og anvendelse
RU2010142486A (ru) Частичный пептид лакритина
ATE218616T1 (de) Humanes zirkulierendes cytokin cc-1
CA2337051A1 (en) Methods for increasing vascularization and promoting wound healing
DE60009926D1 (de) Stabilisierung von gefriergetrocknetem kuchen
DE69831979D1 (de) Gefrorenes lebensmittel
DE60227670D1 (de) Aminosäuren-enthaltende zusammensetzungen, geeignet zur wundheilung, insbesondere zur behandlung des auges
PT1296675E (pt) Composicoes a base de aminoacidos apropriadas para o tratamento da insuficienciacardiaca
KR927003514A (ko) 양쪽성 또는 쯔비터이온성 계면활성제의 후처리 방법
JPS56103106A (en) Protective agent of hair for permanent wave
ATE299028T1 (de) Behandlung von krebserkrankungen mit aplidin in kombination mit carnitin oder acetylcarnitin
DK0793503T3 (da) Anvendelse af hepatocyt-vækstfaktor til inducering af profilerering og differentiering af hemotopoietiske celler
PE20040537A1 (es) Fitasas modificadas
EP1282434A4 (de) METHODE ZUR ZELLADHäSION UND WUNDHEILUNG
MY142040A (en) Nitrosophenols and c-nitrosoanilines as polymerization inhibitors

Legal Events

Date Code Title Description
8364 No opposition during term of opposition